C07K14/4715

COMPOSITION AND SYSTEM FOR SEPARATING AND DETECTING ALPHA-FETOPROTEIN VARIANT AND USE THEREOF
20180009863 · 2018-01-11 ·

Disclosed are a composition and system for separating and detecting an alpha-fetoprotein variant, comprising a separation reagent and a detection reagent; a system for separating and detecting an alpha-fetoprotein variant and a use thereof; and a kit for separating and detecting the alpha-fetoprotein variant. By means of the composition and system for separating and detecting the alpha-fetoprotein variant, and the use thereof, primary liver cancer can be indicated early on, the sensitivity is high, and the method is rapid, simple and automated.

DETECTION AND TREATMENT OF BREAST CANCER

The present invention describes methods for determining the risk that a breast precursor lesion will progress to invasive breast cancer and/or the risk of recurrent non-invasive disease in a patient, comprising detecting the presence and/or level of PAPA and/or PAPPA functional activity in a breast tissue sample obtained from the patient, wherein if PAPPA is not present, or is present at a reduced amount compared to a control, the is the risk of progression to invasive cancer and/or the risk or recurrent disease.

The present invention also enables the chemosensitisation of mitotically delayed breast cancer cells to anti-proliferative agents, preferably anti-mitotic agents, by restoring normal progression through mitosis. In this embodiment a first drug is applied to release breast cancer cells from the mitotic block and, sequentially, a second drug affecting proliferating cells is administered for cancer cell killing.

MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF
20220089680 · 2022-03-24 ·

The present disclosure provides T-cell modulatory multimeric polypeptides that comprise an immunomodulatory polypeptide and that comprise an epitope-presenting alpha-feto protein peptide. A T-cell modulatory multimeric polypeptide is useful for modulating the activity of a T cell, and for modulating an immune response in an individual.

ANTIGEN TREATMENT METHOD

What is required is a method of producing, without treating a glycoprotein in a biological sample with a denaturing agent in advance, a selectively binding material, which specifically reacts with a glycan of a glycoprotein, a selectively binding material such as antibody thus produced by the method, and a method of specifically detecting a glycoprotein by using the selectively binding material.

In order to solve the problems, the present invention produces a selectively binding material specifically reactive with a glycan of a glycoprotein by treating the glycoprotein with a glycan-specific glycan-cleaving enzyme.

PLACENTAL LIPID BILAYER FOR CELL-FREE MOLECULAR INTERACTION STUDIES
20200370008 · 2020-11-26 ·

The invention provides a lipid bilayer mimicking the lipid composition of the placenta. The lipid composition provides an in vitro placenta model using the lipid composition of the placental cell membrane.

PIF-TRANSFECTED CELLS AND METHODS OF USE
20200353038 · 2020-11-12 ·

Cells transfected with DNA sequences encoding for a PreImplantation Factor (PIF) or a PIF and one or more fusion tag(s) are disclosed. Also disclosed are DNA sequences encoding for synthetic PIFs, a PIF fusion peptide made of a PIF and one or more fusion tags, methods of treatment using the transfected cells that express a PIF, an R-I-K-P peptide, compositions containing the R-I-K-P peptide, and methods of identifying a compound that binds to an active site of an WX.sub.1WX.sub.2X.sub.3X.sub.4REWFX.sub.5X.sub.6X.sub.7W receptor, wherein each X can be any amino acid.

BLOCKADE OF ALPHAFETOPROTEIN (AFP) INTERACTIONS WITH BETA2-MICROGLOBULIN ASSOCIATED MOLECULES

Provided herein, in some aspects, are compositions and methods to inhibit AFP interactions with 2M and/or Class I-related molecule interactions in diseases or disorders where elevated AFP levels are associated with immunosuppression. Also provided herein, in some aspects, are compositions and methods to enhance or potentiate AFP interactions with 2M and/or Class I-related molecule in diseases or disorders with decreased AFP levels or diseases or disorders where increasing AFP levels is desired to increase immunosuppression or enhance organ regeneration.

Composition and system for separating and detecting alpha-fetoprotein variant and use thereof

Disclosed are a composition and system for separating and detecting an alpha-fetoprotein variant, comprising a separation reagent and a detection reagent; a system for separating and detecting an alpha-fetoprotein variant and a use thereof; and a kit for separating and detecting the alpha-fetoprotein variant. By means of the composition and system for separating and detecting the alpha-fetoprotein variant, and the use thereof, primary liver cancer can be indicated early on, the sensitivity is high, and the method is rapid, simple and automated.

LIMITED SELF-REPLICATING MRNA MOLECULAR SYSTEM, PRODUCING METHOD AND USE
20240200042 · 2024-06-20 ·

The application relates to the technical field of biomedicine, in particular to a limited self-replicating mRNA molecular system, producing method and use. The limited self-replicating mRNA molecular system including: a first mRNA encoding a mutated alphavirus replicase; and at least one second mRNA encoding a target protein; by generating specific mutation adjustments in the nsP2 subunit of mutated replicase, this limited self-replicating mRNA molecular system can achieve limited self-replication and avoid cytotoxicity; by constructing different mRNA with mutated alphavirus replicase and different target proteins, the mutated alphavirus replicase encoded by the first mRNA can simultaneously replicate multiple different target proteins, achieving sustained expression of multiple target proteins.

PREGNANCY ASSOCIATED GLYCOPROTEIN (PAG) GENES AS MARKERS OF BULL FERTILITY
20190002978 · 2019-01-03 ·

A method for selecting for enhanced fertility of a male mammal includes obtaining one or more samples of a cell or tissue from a plurality of male mammals and quantifying one or both of a blood pregnancy-associated glycoprotein (PAG) concentration or a PAG genomic DNA in the one or more samples of a cell or tissue. Male mammals of the plurality of male mammals exhibiting a highest circulating PAG and/or a highest PAG genomic DNA are selected. Cells/tissues from the selected male mammals may be utilized in a reproductive procedure. Kits for accomplishing the methods are provided.